1 / 15

Substance Use Disorder

Definition (DSM-V) 1 “A cluster of cognitive, behavioral and physiological symptoms indicating that the individual continues using the substance despite significant substance-related problems ” Diagnostic criteria Impaired control over substance use Social impairment due to use

ananda
Télécharger la présentation

Substance Use Disorder

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Definition (DSM-V)1 • “A cluster of cognitive, behavioral and physiological symptoms indicating that the individual continues using the substance despite significant substance-related problems” • Diagnostic criteria • Impaired control over substance use • Social impairment due to use • Risky use (eg, while driving) • Pharmacological criteria (tolerance, withdrawal) Substance Use Disorder American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013.

  2. BDZs and Z-drugs (zopiclone, zolpidem, and zaleplona) • Used by 9% of Canadians aged ≥15 years1 • Enhance GABA by binding to the alpha-1 subunit of GABAA receptors • Common adverse effects: daytime drowsiness, dizziness, agitation, hallucinations, sleepwalking Sedative Hypnotic Anxiolytic (SHA) Agents BDZ = benzodiazepine; GABA = gamma aminobutyric acid a Approved by Health Canada but no longer marketed Health Canada. Canadian Alcohol and Drug Use Monitoring Survey. 2011.

  3. Results in clinically significant impairment or distress, and characterized by ≥2 of the following elements over a 12-month period: • Consumption in higher quantities and/or for longer duration than intended • Persistent urge or multiple attempts to reduce use • Time and effort devoted to the substance • Craving or strong desire to take the substance • Impairment of responsibilities and duties • Impairment in social situations or relationships • Avoidance or reduced time devoted to important activities • Use in physically dangerous situations • Consumption despite awareness of causing/worsening a health problem • Tolerance • Withdrawal signs and symptoms Summary of DSM-V Classification of SHA Use Disorder American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013.

  4. SHAs account for <1% of all admissions for addiction treatment services1 • United States data: 0.3% in 12–17-year-olds; 0.2% in adults2 • Prevalence lowest in population ≥65 years old • Abuse/dependence associated with zolpidem and zopiclone significantly lower than with BDZs3 How Prevalent is SHA Use Disorder? Pirsi A; Centre for Addiction and Mental Health. CrossCurrents. 2011;14(3). American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 2013. Hajak G et al. Addiction. 2003;98(10):1371-1378.

  5. Establish an open and accepting relationship • Conduct regular follow-up visits • Clarify target symptoms to be treated • Consider alternative/complementary management • Ask about family history of substance use disorder • Do a thorough history: medical, psychiatric, and alcohol/drug use • Assess psychosocial factors How Can I Safely Prescribe an SHA?

  6. Perform a sleep history if insomnia is presenting complaint • Seek an organic cause for insomnia • Where possible, avoid: • Agents with a rapid entry into / more potent effect on central nervous system • Long-acting BDZs, especially in elderly • Stress that medication is intended for short-term use only and should be used as directed How Can I Safely Prescribe an SHA?cont.

  7. Factors in not screening patients • Lack of information on how to support patients with substance use problems • Desire to avoid causing patients discomfort or embarrassment • Time • Stepped approach to screening • No concerns with patient: 1-2 questions • Clinically based concern: schedule follow-up • General screening tools for substance use disorder • NIDA-Modified ASSIST • CAGE questionnaire (Cut down, Annoyed, Guilty, Eye opener) • 5 A’s (Ask, Advise, Assess, Assist, Arrange) How Do I Screen for an SHA Use Disorder in One of My Patients?

  8. Benzodiazepine Tapering Strategies: Outpatients • Switch to a longer-acting benzodiazepine • Convert to the equivalent dose of diazepam (max 80–100 mg/day) in divided doses, adjusting the initial dose according to symptoms • Tapering • Maximum 5 mg per week, or 5 mg every 3-4 days if the starting dose is >50 mg of diazepam equivalent • Adjust the rate of taper according to symptoms • Slow the rate of taper once the dose is <20 mg of diazepam equivalent (eg, 2–4 mg/week) • Depending on patient reliability, consider daily, biweekly, or weekly dispensing

  9. Benzodiazepine Tapering Strategies: Inpatients • Start the taper at 1/2 to 1/3 the diazepam equivalent, administering in bid–tid doses • If the patient experiences significant withdrawal on this dose, increase the next day dose by 10–30 mg • The patient can be given 10–15 mg of diazepam for acute withdrawal symptoms during the taper • Hold diazepam and decrease the daily dose if the patient experiences sedation or drowsiness • Taper by 10–15 mg/day • Once the patient reaches a daily dose of <50 mg, treatment can be switched over to outpatient

  10. Signs and Symptoms of SHA Withdrawal • Autonomic hyperactivity • eg, perspiration, tachycardia, hypertension • Increased hand tremor • Insomnia • Nausea or vomiting • Transient visual, tactile, or auditory illusions • Psychomotor agitation • Anxiety and panic attacks • Grand mal seizures • Delirium, psychosis, and cardiac abnormalities (select cases)

  11. Alcohol • Alcohol reduces sleep-onset latency, but sleep is usually shallow and disrupted • Increases snoring, upper airway resistance, and apneic events, even if no apnea history1,2 • Sleep severely disturbed with chronic alcohol use3 • Prolonged sleep latency • Decreased SWS and REM sleep • Poor sleep efficiency • Greater sleep disruption • Sleep disruption in recovering alcoholics can be prolonged (up to 27 months)4 and increases risk of relapse SWS = slow-wave sleep; REM = rapid eye movement Scanlon MF et al. EurRespir J. 2000;16(5):909-913. Young T et al. Am J RespirCrit Care Med. 2002;165(9):1217-1239. Gillin JC et al. Am J Psychiatry. 1990;147(1):106-109. Cohn TJ et al. Addict Biol. 2003;8(4):455-462.

  12. Over-the-counter Sleep Agents • First-generation antihistamines • Induce drowsiness by inhibiting histamine-1 receptor • Duration of action: 4–6 hours • Decrease sleep latency and nocturnal awakenings, increase sleep duration and quality1,2 • Potential adverse events: daytime sedation, impaired psychomotor performance, dizziness, and tinnitus • Caution with elderly patients due to possible cognitive impairment3 Kolla BP et al. Alcohol. 2011;46(5):578-585. Kudo Y and Kurihara M. J ClinPharmacol. 1990;30(11):1041-1048. Basu R et al. Am J Geriatr Psychiatry. 2003;11(2):205-213.

  13. Over-the-counter Sleep Agents cont • Substance-related disorder can occur • Common pleasant effects: antianxiety, antidepressant, and euphoria/pleasure • Chronic users of high doses can experience significant withdrawal symptoms: dysphoria, agitation, nausea, and cravings • Withdrawal associated with nausea and anxiety; can last up to 10 days

  14. Other Substances: Cannabis • Effect on sleep unclear • Subjective effect: induces relaxation and drowsiness • Objective effect: appears to decrease sleep latency and amount/density of REM sleep, and increases SWS1 • Chronic use: tolerance to effects on SWS and sleep latency, but effects on REM sleep persist2 • Higher doses may increase sleep latency3 • Acute discontinuation appears to cause rebound • Sleep disturbance cited as a reason for relapse4 Cousens K, DiMascio A. Psychopharmacologia. 1973;33(4):355-364. KaracanI et al. Ann N Y Acad Sci. 1976;282:348-374. Tassinari CA et al. In: Pharmacology of Marijuana. New York (NY). 1976. KouriEMand Pope HG Jr. ExpClinPsychopharmacol. 2000;8(4):483-492.

  15. Other Substances: Opioids • Most commonly abused: codeine, morphine, hydromorphone, and oxycodone • Cause sedation, but reduce total and REM sleep time on first administration (drug-naïve) • Tolerance occurs quickly, requiring dose escalation to achieve effects (including sedation) • Sleep disrupted/suppressed during withdrawal; prolonged insomnia is a risk factor for relapse1 Gillin JC et al. In: Principles and Practice of Sleep Medicine, 4th ed. Philadelphia (PA): Elsevier Saunders; 2005:1345-1358.

More Related